about
Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Identification of Highly Potent Protein Kinase C-Related Kinase 1 Inhibitors by Virtual Screening, Binding Free Energy Rescoring, and in vitro Testing.Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs.Chemical Proteomics Reveals Ferrochelatase as a Common Off-target of Kinase Inhibitors.Evaluation of Kinase Activity Profiling Using Chemical Proteomics.New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.Probing SH2-domains using Inhibitor Affinity Purification (IAP).Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies.ML3 is a NEDD8- and ubiquitin-modified protein.Pharmacoproteomic characterisation of human colon and rectal cancer.The target landscape of clinical kinase drugs.Optimized chemical proteomics assay for kinase inhibitor profiling.Increased Pancreatic Protease Activity in Response to Antibiotics Impairs Gut Barrier and Triggers ColitisDENEDDYLASE1 deconjugates NEDD8 from non-cullin protein substrates in Arabidopsis thalianaA new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitorsChemoproteomic Selectivity Profiling of PIKK and PI3K Kinase InhibitorsCiRCus: A Framework to Enable Classification of Complex High-Throughput ExperimentsThe Formation of a Camalexin Biosynthetic Metabolon
P50
Q30313903-B6741232-45D3-4E50-9E1F-421E95BA4AA0Q36089876-B4989DD0-AA81-43E7-A2A7-EB411C632E07Q38702282-9A2B5EAF-0679-46DB-84B8-E85946DDBD0FQ38739129-E8ED70C3-7044-4016-9CAB-E39FDD4ED86BQ38795227-D6668E6D-4095-4EEC-925A-7237B36DC099Q38834756-820FD9DE-78CC-4A67-B726-A49E40A3296AQ39006491-FD7293D1-51CC-4A84-BFBC-9E4D3A89B837Q39153022-C6874D1A-DA59-4431-88E4-6A681E14AA8FQ41989875-CE38EDF7-892C-4E72-9F91-D0C94AB65387Q44508494-1071CE8F-0E75-49FB-B11B-CAFA6670C6BEQ47205259-D73825B7-BA69-4DBB-BF58-ED22C1BBD21DQ47345032-9221AAFD-91A1-451A-A780-263FBE19D52CQ54292023-203CB465-5AF8-4F6D-A4CD-19341CDD7932Q58001179-89F1E31E-DB0C-4121-AB5F-A61652335A8EQ58001200-43C98772-B48A-47C1-8245-03816CF6EB5DQ58001212-0856B743-6ECA-4A93-A2BD-DC214F6B8DE8Q63352299-F96E588D-3BB2-4F48-BAF6-B5EAF2D64DA6Q63352302-C92ECA52-F133-4FC7-BD56-6827F568CD28Q90067850-54C9877A-02D3-4D98-A45D-082B043D5E7C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Stephanie Heinzlmeir
@ast
Stephanie Heinzlmeir
@en
Stephanie Heinzlmeir
@es
Stephanie Heinzlmeir
@nl
type
label
Stephanie Heinzlmeir
@ast
Stephanie Heinzlmeir
@en
Stephanie Heinzlmeir
@es
Stephanie Heinzlmeir
@nl
prefLabel
Stephanie Heinzlmeir
@ast
Stephanie Heinzlmeir
@en
Stephanie Heinzlmeir
@es
Stephanie Heinzlmeir
@nl
P106
P31
P496
0000-0002-1066-6565